Skip to main content

Table 2 Patient and tumour characteristics subgrouped according to high or low thymidine phosphorylase expression

From: Thymidine phosphorylase expression is associated with time to progression in patients with metastatic colorectal cancer

 

Patient cohort

Patient subgroup for serum analysis*

 

(n = 125)

(n = 70)

 

tTP high

tTP low

sTP high

sTP low

Age (year)

    

  Median (IQR)

68 (59–75)

64 (57–73)

66 (56–75)

65 (59–74)

Gender (%)

    

  Female

27 (44)

31 (49)

15 (43)

12 (34)

  Male

35 (56)

32 (51)

20 (57)

23 (66)

Tumour location (%)

    

  Colon

26 (42)

43 (68)

21 (60)

18 (51)

  Rectum

36 (58)

20 (32)

14 (40)

17 (49)

Tumour stage (%)

    

  I

4 (6)

-

1 (3)

-

  II

17 (27)

4 (6)

6 (17)

6 (17)

  III

24 (39)

27 (43)

12 (34)

16 (46)

  IV

17 (27)

32 (51)

16 (46)

13 (37)

Tumour differentiation (%)

    

  Well

1 (2)

1 (2)

-

1 (3)

  Medium

42 (68)

36 (57)

23 (66)

23 (66)

  Poor

16 (26)

20 (32)

9 (26)

8 (23)

  Mucinous

2 (3)

6 (10)

3 (9)

3 (8)

  Unknown

1 (2)

-

-

-

Assessed lymph nodes, median (IQR)

17 (12–24)

19 (16–25)

17 (14–26)

21 (14–29)

Positive lymph nodes, median (IQR)

1 (0–6)

4 (2–8)

3 (0–8)

3 (1–9)

T-stage (%)

    

  1

-

-

-

-

  2

8 (13)

-

2 (6)

2 (6)

  3

36 (58)

32 (51)

16 (46)

19 (54)

  4

13 (21)

25 (40)

15 (43)

14 (40)

Not evaluable

5 (8)

6 (10)

2 (6)

-

N-stage (%)†‡

    

  0

25 (40)

6 (10)

9 (26)

8 (23)

  1a

8 (13)

9 (14)

6 (17)

5 (14)

  1b

6 (10)

11 (17)

2 (6)

5 (14)

  2a

9 (14)

15 (24)

7 (20)

5 (14)

  2b

13 (21)

22 (35)

10 (28)

12 (34)

  X

1 (2)

-

1 (3)

-

Metastatic sites (%)

    

  Liver

24 (39)

27 (43)

13 (37)

19 (549

  Pulmonary

3 (5)

3 (5)

1 (3)

2 (6)

  Skeletal

-

1 (2)

-

-

  Local

3 (5)

2 (3)

3 (9)

-

  Multiple including liver

19 (31)

17 (27)

13 (37)

5 (14)

  Multiple excluding liver

8 (13)

10 (16)

4 (11)

4 (11)

  Lymphatic

5 (8)

3 (5)

1 (3)

5 (14)

  1. Sum of percentages may not add up to 100 due to rounding.
  2. Abbreviations: tTP tumour thymidine phosphorylase, sTP serum thymidine phosphorylase, IQR interquartile range.
  3. *Serum was obtained from 70 patients.
  4. †TNM, 7th edition from UICC/AJCC (Union for International Cancer Control/American Joint Committee on Cancer).
  5. ‡Data missing on one patient due to palliative surgery.